ISEGORIA

Neuropharmacology research model

Concerta across the active day.

A dose-time model connecting OROS methylphenidate exposure to DAT/NET occupancy and relative extracellular dopamine and norepinephrine signals.

Not a dosing guide. Human studies do not directly measure minute-by-minute synaptic NE and DA after Concerta. The transmitter curves are evidence-anchored inferences with substantial uncertainty. The 2026 US and Australian product information cap recommended adult dosing at 72 mg/day.
54 mg72 mg90 mg108 mg
72 mg

Plasma exposure

Central adult estimate; dose-proportional scaling from a 54 mg reference profile.

Transporter occupancy

Saturable PET-informed engagement; EC50 5.7 ng/mL (DAT), 4.7 ng/mL (NET).

DATNET

Relative extracellular transmitter signal

Striatal DA is human-PET anchored; NET-rich-region NE magnitude is hypothesis-grade.

DANE proxy
Selected time8.0 h
Plasma-
DAT / NET-
DA increase-
NE proxy-

What can be inferred

Concerta produces an early 1-2 hour shoulder, a broader 6-8 hour peak, and a gradual decline. Plasma exposure rises approximately in proportion to dose over 54-108 mg, but transporter occupancy is saturable. The modeled difference between 90 and 108 mg is therefore smaller for extracellular effect than for plasma concentration.

Regional meaning

The DA curve represents a striatal signal, where DAT is prominent. In prefrontal cortex, NET also clears dopamine, so a single whole-brain dopamine curve would be misleading.

Uncertainty

Body size, metabolism, age, food timing, neural firing, sleep, prior treatment, comorbidity, interacting medicines, and the formulation itself can move an individual far from the central trace. The plot predicts neither subjective experience nor clinical benefit.

Download the 7-page report (PDF)